Page last updated: 2024-11-05

pentafluorobenzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Pentafluorobenzoic acid (PFBA) is a highly fluorinated aromatic carboxylic acid. It is a colorless solid with a melting point of 103-104 °C and a boiling point of 245 °C. PFBA is synthesized by the reaction of pentafluorobenzene with carbon dioxide in the presence of a strong base, such as potassium hydroxide. It is a versatile building block for the preparation of other fluorinated compounds, including pharmaceuticals, agrochemicals, and materials science. PFBA has been studied for its potential use as a flame retardant, a surfactant, and a component of lithium-ion batteries. It is also used as a reagent in organic synthesis and as a standard in analytical chemistry. PFBA is known to be a potent inhibitor of the enzyme carbonic anhydrase, which is involved in the regulation of carbon dioxide levels in the body. Studies have shown that PFBA can have adverse effects on the environment and human health, including toxicity to aquatic organisms and potential endocrine disruption.'

Cross-References

ID SourceID
PubMed CID11770
CHEMBL ID3092378
CHEBI ID46796
SCHEMBL ID203915
MeSH IDM0239971

Synonyms (39)

Synonym
nsc88337
perfluorobenzoic acid
nsc-88337
602-94-8
2,3,4,5,6-pentafluoro-benzoic acid
pentafluorobenzoic acid
benzoic acid, pentafluoro-
nsc 88337
einecs 210-026-6
brn 2054395
2,3,4,5,6-pentafluorobenzoic acid, 99%
CHEBI:46796 ,
2,3,4,5,6-pentafluorobenzoic acid
NCIOPEN2_005348
AC-4654
yzerdtreousuhf-uhfffaoysa-
inchi=1/c7hf5o2/c8-2-1(7(13)14)3(9)5(11)6(12)4(2)10/h(h,13,14)
P0806
AKOS000119713
A8421
2,3,4,5,6-pentafluorobenzoicacid
c7hf5o2
benzoic acid, 2,3,4,5,6-pentafluoro-
b4jcp8r5gj ,
unii-b4jcp8r5gj
4-09-00-00956 (beilstein handbook reference)
FT-0609327
CHEMBL3092378
SCHEMBL203915
DTXSID4060527
W-105266
mfcd00002406
D72572
CS-0030580
AS-11945
EN300-20106
AMY3640
PB47373
Z104476874

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Urinary excretion in bile-cannulated animals was similar to that found in studies using non-cannulated animals dosed at 100mg kg(-1)."( Application of (1)H- and (19)F-NMR spectroscopy in the investigation of the urinary and biliary excretion of 3,5-, 2,4-ditrifluoromethylbenzoic and pentafluorobenzoic acids in rat.
Blackledge, CA; Evans, JA; Nicholson, JK; Rodgers, C; Wilson, ID, 2002
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
perfluorinated compoundAn organofluorine compound containing only C-F bonds (no C-H bonds) and C-C bonds but also other heteroatoms (particularly other halogens, oxygen, and sulfur). Their properties represent a blend of fluorocarbons (containing only C-F and C-C bonds) and the parent functionalised organic species.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1059430Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (12.50)18.2507
2000's9 (56.25)29.6817
2010's5 (31.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.52 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index31.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]